From 251379bc14b7fe7ab29a71f0f71becbb3ad62044 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Thu, 19 Mar 2026 04:30:23 +0000 Subject: [PATCH] extract: 2026-03-19-glp1-price-compression-international-generics-claim-challenge Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...net cost impact inflationary through 2035.md | 6 ++++++ ...on-international-generics-claim-challenge.md | 17 ++++++++++++++++- 2 files changed, 22 insertions(+), 1 deletion(-) diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 64f46f58..8a55608b 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -107,6 +107,12 @@ Value in Health modeling study shows Medicare saves $715M over 10 years with com Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow only 2% after 12 months (vs 6% for non-users), with diabetes patients showing 6-9 percentage point lower cost growth at 30 months. This suggests the 'inflationary through 2035' claim may only apply to short-term payers, while long-term risk-bearers see net savings. + +### Additional Evidence (challenge) +*Source: [[2026-03-19-glp1-price-compression-international-generics-claim-challenge]] | Added: 2026-03-19* + +International generic competition beginning January 2026 (Canada patent expiry, immediate Sandoz/Apotex/Teva filings) creates price compression trajectory faster than 'inflationary through 2035' assumes. Oral Wegovy launched at $149-299/month (5-8x reduction vs $1,300/month injectable). China/India generics projected at $40-50/month by 2030. Aon 192K patient study shows break-even timing is highly price-sensitive: at $1,300/month, multi-year retention required; at $50-150/month, Aon data suggests cost savings within 12-18 months under capitation. The 'inflationary through 2035' conclusion holds at current US pricing but becomes invalid if international generic arbitrage and oral formulation competition compress effective prices to $50-150/month range by 2030. Scope qualification needed: claim is valid conditional on pricing trajectory assumptions that are now challenged by G7 patent cliff precedent. + --- Relevant Notes: diff --git a/inbox/queue/2026-03-19-glp1-price-compression-international-generics-claim-challenge.md b/inbox/queue/2026-03-19-glp1-price-compression-international-generics-claim-challenge.md index 9b039b09..9ebbfa32 100644 --- a/inbox/queue/2026-03-19-glp1-price-compression-international-generics-claim-challenge.md +++ b/inbox/queue/2026-03-19-glp1-price-compression-international-generics-claim-challenge.md @@ -7,10 +7,14 @@ date: 2026-03-19 domain: health secondary_domains: [internet-finance] format: synthesis -status: unprocessed +status: enrichment priority: high tags: [glp-1, generics, patent-cliff, price-trajectory, cost-effectiveness, kb-claim-challenge, scope-qualification] flagged_for_rio: ["GLP-1 price compression changes the investment economics for risk-bearing health plans — shorter time horizon to net savings under capitation"] +processed_by: vida +processed_date: 2026-03-19 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -96,3 +100,14 @@ PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic catego WHY ARCHIVED: This is a direct scope challenge to the existing claim. The GLP-1 patent cliff data (GeneOnline) is already in queue but unprocessed; this synthesis connects it to the Aon cost data and makes the scope challenge explicit for the extractor. EXTRACTION HINT: Don't extract a new claim — update/scope-qualify the existing GLP-1 claim. The extractor should add a `challenged_by` reference and update the claim body with the price trajectory sensitivity analysis. + + +## Key Facts +- Canada semaglutide patents expired January 4, 2026 with immediate generic filings from Sandoz, Apotex, Teva +- Brazil and India GLP-1 patent expirations March 2026 +- China has 17+ generic GLP-1 candidates in Phase 3 trials +- Oral Wegovy launched January 2026 at $149-299/month vs $1,300/month for injectable semaglutide +- Medicare negotiated semaglutide rate: $245/month +- US/Europe GLP-1 patents extend to 2031-2032 +- Orforglipron (Lilly non-peptide oral GLP-1) potential approval Q2 2026 +- Amycretin shows 22% weight loss without plateau in trials